Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of HPV-negative head and neck squamous cell carcinoma
Economic impact of diagnostic testing
4 evidence topics · 6 sources
PD-L1 testing requirement in the pembrolizumab label
PD-L1 testing patterns before first-line therapy in US practice
“Adults with R/M HNSCC initiating 1L systemic therapy were included from a U.S. nationwide database primarily compromised of community practices (07/01/2019-12/31/2023).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 2,207 patients, 32.7 % received PD-L1 testing before 1L therapy initiation, 17.4 % after 1L therapy initiation, and 50.0 % were never tested.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This study revealed low utilization of PD-L1 testing to guide treatment choice and impactful gaps between specimen collection, the receipt of results, and 1L therapy initiation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HPV testing rates in oropharyngeal squamous cell carcinoma
“Among the 146,176 patients with OPSCC and known HPV testing included in the study, the overall HPV testing rate was 88.4% (N = 129,240/146,176). Testing for HPV mediation significantly increased during the study period from 56.0% to 93.6% (adjusted odds ratio [OR]: 1.23, 95% CI: 1.22-1.24, P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HPV testing methods recommended by the College of American Pathologists
“For oropharyngeal tissue specimens (i.e. non-cytology), including regional lymph nodes with metastatic SCC and clinical findings consistent with an oropharyngeal primary, pathologists should perform HR-HPV testing by surrogate marker p16 IHC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pathologists should not routinely perform HR-HPV testing on patients with primary oral cavity, laryngeal, nasopharyngeal, or hypopharyngeal SCCs of the head and neck for prognostic purposes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote